The evaluation of metabolic syndrome in patients diagnosed with non-alcoholic fatty liver disease (NAFLD): a cross-sectional study of Iranian population

Document Type : Original Article

Authors

1 Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Social Medicine, Faculty of Medicine, Mashhad University

10.30483/rijm.2021.249754.0

Abstract

Introduction:
Our study is assessing the epidemiological aspects of nonalcoholic fatty liver disease (NAFLD) in Iranian population and evaluates the relationship between NAFLD and metabolic syndrome.
Methods and Materials:
We conducted this cross-sectional study on 145 subjects who were diagnosed with NAFLD and referred to the Gastroenterology clinics of Ghaem Hospital, Mashhad, Iran in the year of 2013. Using ultrasonography method, we diagnosed NAFLD as a fatty liver manifestation in the absence of other liver complications. We used National Cholesterol Education Program Adult Treatment Panel III criteria (ATPIII) as a guideline to establish metabolic syndrome diagnosis.
Results:
Metabolic syndrome had an overall prevalence of 49.7% among our subjects. The results showed no difference in mean AST and ALT levels between the groups of patients with and without metabolic syndrome. Our results were unable to maintain an association between our targeted liver enzymes (AST and ALT) and different features of metabolic syndrome. In multivariate linear regression models, the presence of metabolic syndrome was unable to predict AST (p=0.631, r2=0.002) or ALT (p=0.122, r2=0.017) abnormalities.
Conclusion:
The present study has shown a high prevalence of metabolic syndrome in Iranian patients who diagnosed with NAFLD. Contrary to previous reports, despite the high prevalence of metabolic syndrome conditions in NAFLD patients, we found that the presence of metabolic syndrome had not increased the risk of NAFLD in the population undergone our study.

Keywords


1.Sonsuz A, Basaranoglu M, Ozbay G. Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis. Am J 
Gastroenterol. 2000;95(5):1370-1.
78
Sajjadi S. et al.
Razavi Int J Med. 2021; 9(3):e845
2. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 
2010;28(1):155-61.
3. Abd El-Kader SM, El-Den Ashmawy EM. Non-alcoholic fatty liver disease: The diagnosis and management. 
World J Hepatol. 2015;7(6):846-58.
4. Law K, Brunt EM. Nonalcoholic fatty liver disease. 
Clin Liver Dis. 2010;14(4):591-604.
5. Pacifico L, Poggiogalle E, Cantisani V, Menichini G, 
Ricci P, Ferraro F, et al. Pediatric nonalcoholic fatty liver disease: A clinical and laboratory challenge. World J 
Hepatol. 2010;2(7):275-88.
6. Sanyal AJ, American Gastroenterological A. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123(5):1705-25.
7. Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, 
Loria P, et al. From NAFLD in clinical practice to answers 
from guidelines. J Hepatol. 2013;59(4):859-71.
8. Khov N, Sharma A, Riley TR. Bedside ultrasound in 
the diagnosis of nonalcoholic fatty liver disease. World J 
Gastroenterol. 2014;20(22):6821-5.
9. Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli 
E, Nascimbeni F, et al. Nonalcoholic fatty liver disease is 
associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence 
from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(5):936-44.
10. Maheshwari A, Thuluvath PJ. Endocrine diseases and 
the liver. Clin Liver Dis. 2011;15(1):55-67.
11. Caserta CA, Mele A, Surace P, Ferrigno L, Amante A, 
Messineo A, et al. Association of non-alcoholic fatty liver 
disease and cardiometabolic risk factors with early atherosclerosis in an adult population in Southern Italy. Ann Ist 
Super Sanita. 2017;53(1):77-81.
12. Amirkalali B, Poustchi H, Keyvani H, Khansari MR, 
Ajdarkosh H, Maadi M, et al. Prevalence of Non-Alcoholic Fatty Liver Disease and Its Predictors in North of Iran. 
Iran J Public Health. 2014;43(9):1275-83.
13. Lankarani KB, Ghaffarpasand F, Mahmoodi M, Lotfi 
M, Zamiri N, Heydari ST, et al. Non alcoholic fatty liver 
disease in southern Iran: a population based study. Hepat 
Mon. 2013;13(5):e9248.
14. Grundy SM, Hansen B, Smith SC, Jr., Cleeman JI, 
Kahn RA, American Heart A, et al. Clinical management 
of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues 
related to management. Circulation. 2004;109(4):551-6.
15. Kotronen A, Westerbacka J, Bergholm R, Pietilainen 
KH, Yki-Jarvinen H. Liver fat in the metabolic syndrome. 
J Clin Endocrinol Metab. 2007;92(9):3490-7.
16. Chen SH, He F, Zhou HL, Wu HR, Xia C, Li YM. 
Relationship between nonalcoholic fatty liver disease and 
metabolic syndrome. J Dig Dis. 2011;12(2):125-30.
17. Hamaguchi M, Takeda N, Kojima T, Ohbora A, 
Kato T, Sarui H, et al. Identification of individuals with 
non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World J Gastroenterol. 
2012;18(13):1508-16.
18. Uchil D, Pipalia D, Chawla M, Patel R, Maniar S, 
Narayani, et al. Non-alcoholic fatty liver disease (NAFLD)--the hepatic component of metabolic syndrome. J 
Assoc Physicians India. 2009;57:201-4.
19. Fattahi MR, Niknam R, Safarpour A, Sepehrimanesh 
M, Lotfi M. The Prevalence of Metabolic Syndrome In 
Non-alcoholic Fatty Liver Disease; A Population-Based 
Study. Middle East J Dig Dis. 2016;8(2):131-7.
20. Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005;43(3):508-14.
21. Hu X, Huang Y, Bao Z, Wang Y, Shi D, Liu F, et al. 
Prevalence and factors associated with nonalcoholic fatty 
liver disease in Shanghai work-units. BMC Gastroenterol. 
2012;12:123.
22. Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, et al. Prevalence and associated metabolic factors of 
nonalcoholic fatty liver disease in the general population 
from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47(5):586-95.
23. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, 
Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 
2003;37(4):917-23.
24. Marchesini G, Marzocchi R. Metabolic syndrome and 
NASH. Clin Liver Dis. 2007;11(1):105-17, ix.
25. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr. 
1999;18(6):353-8.
26. Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, et al. Increased prevalence 
of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut. 
2004;53(7):1020-3.
27. Hsiao PJ, Kuo KK, Shin SJ, Yang YH, Lin WY, Yang 
JF, et al. Significant correlations between severe fatty liver 
and risk factors for metabolic syndrome. J Gastroenterol 
Hepatol. 2007;22(12):2118-23